Description
Metformin 1000 mg Actavis — metformin from Actavis at 1000 mg. Biguanide reducing hepatic glucose production and improving insulin sensitivity. First-line type-2 diabetes therapy; off-label glucose management during HGH cycles.
Key Benefits
- First-line T2DM medication — biguanide class
- Glucose control via hepatic gluconeogenesis suppression
- Modest weight-loss effect in non-diabetic users
- Insulin-sensitisation — useful on HGH/GH-axis compound cycles
- Oral dosing, start low to minimise GI side-effects
- Each unit dosed at 1000 mg — see Recommended Dosage below for protocol-specific intake
How It Works
Activates AMPK in hepatocytes, suppressing gluconeogenesis. Reduces fasting glucose, HbA1c, and improves insulin sensitivity. Modest weight-loss effect in insulin-resistant individuals. Not directly a fat-burner.
Pharmacokinetics
Plasma half-life approximately 6 hours. Twice-daily immediate-release or once-daily extended-release. Not metabolised — renally excreted. Monitor kidney function in long-term users.
Potential Side Effects
GI upset (nausea, diarrhoea, bloating) common during titration — resolves at stable dose. Vitamin B12 depletion on long runs — supplement. Rare lactic-acidosis risk in kidney-impaired users.
Cycle & Stacking Guide
Long-term T2DM treatment. For performance users: insulin-sensitisation during HGH cycles at 500–1000 mg/day. Bloodwork every 3 months.
Manufacturer Notes
Actavis is an independent producer in the research-compound market. Before first use, request the batch-specific Certificate of Analysis and confirm the vial’s tamper-evident seal is intact.
Storage & Handling
Store at recommended temperature (15–25°C; peptides and HGH at 2–8°C after reconstitution). Protect from light and moisture. Keep out of reach of children. For research and educational purposes only.
Reviews
There are no reviews yet.